Day: March 29, 2023

WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the full year ended December 31, 2022. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “In 2022, we advanced our cell and gene therapy programs and presented promising research supporting the potential of our clinical portfolio at several prestigious medical meetings. Our lead clinical candidate is MB-106, a CD20-targeted, autologous CAR T cell therapy to treat relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic...

NEWARK, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Concentrix Corporation (NASDAQ: CNXC), a leading global provider of customer experience (CX) solutions and technology, today announced financial results for the fiscal first quarter ended February 28, 2023.  Three Months Ended      February 28, 2023   February 28, 2022   ChangeRevenue ($M) $ 1,636.4     $ 1,536.1     6.5%Operating income ($M) $ 156.0     $ 147.7     5.6%Non-GAAP operating income ($M) (1) $ 217.6     $ 201.9     7.8%Operating margin   9.5 %     9.6 %   -10 bpsNon-GAAP operating margin (1)   13.3 %     13.1 %   20 bpsNet income ($M) $ 87.9     $ 110.3     (20.3)%Non-GAAP net income ($M) (1) $ 134.0     $ 150.7     (11.1)%Adjusted EBITDA ($M) (1) $ 255.8     $ 237.9     7.5%Adjusted EBITDA margin (1)   15.6 %     15.5 %   10 bpsDiluted...

Positive topline data from BDC-1001 dose-escalation clinical study validates the ability of the Boltbody™ ISAC platform to generate anti-tumor activity with acceptable safety BDC-1001 advances into a focused Phase 2 program commencing in 2023: a trial as monotherapy and in combination with nivolumab in colorectal, endometrial, and gastroesophageal cancers; and a second trial in breast cancer studying monotherapy and combination with pertuzumab (Perjeta®) BDC-3042 expected to enter clinic in 2023; upcoming presentation at AACR 2023 Cash balance of $192.8 million anticipated to fund key milestones through 2025REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported...

Total revenue for 2022 was approximately $2.6 million Balance sheet strengthened by recently closed public offering with gross proceeds of $7.5 million Conference call to be held March 29, 2023 at 4:30 p.m. ETROCKVILLE, Md., March 29, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today its fourth quarter 2022 and full-year 2022 financial and operating results and provided a business update. OpGen’s revenue for the fourth quarter of 2022 was approximately $722 thousand. Its total revenue for 2022 was approximately $2.6 million which was in line with the Company’s most recent guidance. “Overall, in 2022 there were several business advancements for OpGen with the...

Full year 2022 Revenue grew to $86.3 million, 10.6% higher compared to 2021 RENO, Nev., March 29, 2023 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and producer of deep cycle lithium-ion storage batteries, today reported financial and operational results for the fourth quarter and full year of 2022. Fourth Quarter 2022 Financial HighlightsNet Sales of $20.2 million were unchanged compared to Q4 2021 Gross Profit of $4.4 million, decreased $1.7 million from $6.1 million in Q4 2021 Operating expenses of $(12.5) million, were higher compared to $(6.2) million in Q4 2021 EBITDA was a negative $(7.8) million, lower compared to $0.1 million in Q4 2021 Adjusted EBITDA was a negative $(4.8) million, compared $1.0 million in Q4 2021Full Year 2022...

Q4 2022 and Full-Year HighlightsAnnual revenue of $101 million, exceeding $100 million for the first time in View’s history, representing 37% year-over-year growth compared to annual revenue of $74 million in 2021 and within management guidance of $100 to $110 million. Record revenues of $44 million for Q4 2022, representing 56% year-over-year growth compared to $28 million in Q4 2021. As of January 1, 2023, View Smart Windows qualify for the Investment Tax Credit (ITC), a 30% to 50% U.S. Federal tax credit intended to drive widespread adoption of smart windows, similar to solar, wind and stand-alone storage technologies. View launched its residential product offering to capitalize on the large and growing opportunity for smart windows in the multi-family sector. View completed a $212 million financing through the sale of convertible...

— ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 — — Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 — — Advancing In-House Manufacturing Capabilities to Prepare for Commercial Production — WATERTOWN, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. “2022 was a transformative year for Lyra. We initiated three clinical trials that we believe will build on the...

ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression Phase 2 go/no-go decisions for ATRC-101 expected by end-of-year APN-497444 and APN-346958 programs advancing with nomination of clinical candidates expected in 2023 Conference call and webcast with accompanying slides scheduled for today at 4:30 p.m. EDT SAN CARLOS, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided...

Conference Call on Thursday, March 30, 2023, at 4 p.m. ET RESTON, Va., March 29, 2023 (GLOBE NEWSWIRE) — Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, announced its financial results for the year ended December 31, 2022 and provided an update on the Company’s continued progress. Significant Milestones in 2022 and year-to-date 2023 include:In February 2023, Lightbridge and Pacific Northwest National Laboratory (PNNL) announced the successful completion of work under the U.S. Department of Energy’s (DOE) Gateway for Accelerated Innovation in Nuclear (GAIN) voucher program to demonstrate Lightbridge’s nuclear fuel casting process using depleted uranium, a key step in manufacturing Lightbridge Fuel™.In February 2023, Lightbridge announced that a recently published peer-reviewed...